You are the first to state what I suspected happened. "They were compelled by shareholders to ask the DMC for an update." Looks like NWBO had to ask the DMC the status of the interim analysis. Otherwise, the DMC may not have reported anything for a while longer. But you and some of the other longs really are seeing things with rose colored glasses. "i.e They are satisfied that there is no safety or futility risk (otherwise they would not have given the decision to continue). " I really doubt that you can objectively come to that conclusion and I won't even state the opposite because that may not be true either. Most likely they are waiting for more data ie. 88events to look for efficacy and trial modifications OR there are lots of scans to look at to see if the DMC interpretation of PFS agrees with the clinicians' interpretation because we are dealing w/ PFS which is not so cut and dried like OS. From what I have seen of other trials the DMC PFS is usually shorter than the clinician's PFS data.
Also, I have a high opinion of Ms. Powers and see nothing wrong with her PR. To read into it as much as some of you have only shows the bias that colors it. Ms. Powers has a lot of skin in her company unlike many CEOs who sell out before an impending decision because they want to "diversify their holding" Also, the failure of DC-Vax L in GBM if it does happen does not spell the end of this co. I am particularly interested in them starting the ovarian cancer trials if that is planned for NWBO. (I get IMUC and NWBO confused so correct me if I am wrong). If GALE's trial is a success then that should be a good sign for NWBO/IMUC
"
News 
Market Data 
Discover 
